

Dr Reddy's Labs

Estimate change	
TP change	
Rating change	

Bloomberg	DRRD IN
Equity Shares (m)	167
M.Cap.(INRb)/(USDb)	1075.9 / 12.4
52-Week Range (INR)	1421 / 1120
1, 6, 12 Rel. Per (%)	-2/-1/4
12M Avg Val (INR M)	2769

Financials & Valuations (INR b)

Y/E MARCH	FY25E	FY26E	FY27E
Sales	323.1	350.1	362.0
EBITDA	88.8	96.3	90.5
Adj. PAT	53.9	62.0	56.8
EBITDA Margin (%)	27.5	27.5	25.0
Adj. EPS (INR)	64.7	74.4	68.2
EPS Gr. (%)	2.0	15.0	-8.3
BV/Sh. (INR)	396	466	529

Ratios

Net D:E	-0.5	-0.6	-0.8
RoE (%)	17.6	17.3	13.7
RoCE (%)	16.4	15.9	12.8
Payout (%)	8.0	6.7	7.4

Valuations

P/E (x)	19.9	17.3	18.9
EV/EBITDA (x)	10.8	9.6	9.5
Div. Yield (%)	0.3	0.3	0.3
FCF Yield (%)	4.7	5.7	7.9
EV/Sales (x)	3.0	2.6	2.4

Shareholding Pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	26.6	26.6	26.7
DII	22.9	21.5	18.7
FII	40.2	41.9	44.1
Others	10.2	10.0	10.6

FII includes depository receipts

CMP: INR1,290

TP: INR1,330 (+3%)

Neutral

Soft g-Revlimid sales, high expenses dent earnings

FY26 to be another year of consolidation

- DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFY25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market.
- We lower our earnings estimates by 5%/3% for FY26/FY27, factoring in 1) a gradual pick-up in potential launches in the NA market, thereby limiting visibility for growth beyond g-Revlimid; and 2) price erosion in the base portfolio. We value DRRD at 20x 12M forward earnings to arrive at a TP of INR1,330.
- DRRD is implementing efforts to build growth levers like a) semaglutide opportunities in Canada and other emerging markets, and b) a niche pipeline (abatacept biosimilar/Iron-sucrose) for the NA market. However, the timing of commercial success of these opportunities and higher anticipated competition in g-Revlimid may keep growth in check for the next two years. Maintain Neutral.

Higher opex impacts profitability YoY

- 3Q revenues grew 14.1% YoY to INR82.3b, adj. for the milestone income of INR1.3b. Adjusting for the accounting related to the NRT acquisition, revenue grew by 8.2% YoY to INR78b (vs. est. of INR76.3b).
- NA sales were stable YoY at INR33.8b (~USD401m; 40% of sales). Europe sales jumped 2.4x YoY to INR12b (14% of sales). Excluding the NRT acquisition, Europe sales grew by 22% YoY, supported by Germany/UK growth of 24%/39% YoY to INR3.3b/INR1.9b. India sales rose 14.1% YoY to INR13.5b (16% of sales). Emerging markets sales grew 12% YoY to INR14.4b (17% of sales). PSAI segment revenue grew 5% YoY to INR8.2b (10% of sales).
- Gross margin (GM) expanded by 190bp YoY to 60.4%, led by margins of PSAI segment (up 830bp YoY), offset by lower margin in GG (down 60bp YoY as % of sales).
- EBITDA margin contracted 30bp YoY to 27.8% (our est: 26.8%), led by higher SG&A/R&D expenses (+140bp/+80 YoY as % of sales).
- EBITDA grew by 7.1% YoY to INR21.7b (vs. est. of INR20.4b).
- PAT was INR13.1b (our est: INR11.9b), down 4.6% YoY.
- During 9MFY25, revenue/EBITDA grew 12.8%/7.1% YoY to INR239b/INR65b. PAT was flat YoY at INR40.7b.

Highlights from the management commentary

- DRRD would file abatacept biosimilar in Dec'25 for US markets.
- It expects steady growth momentum in the Russia market (+19% YoY in 3Q).
- DRRD indicated Canada, India and Brazil will be initial focus markets for Semaglutide over the next 12-18 months.

Quarterly Performance - IFRS											(INRb)		
Y/E March	FY24				FY25E				FY24E	FY25E	Estimates		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	3Q-Adj.	4QE		3QE	% Var	
Sales	67.4	68.8	72.1	70.8	76.7	80.2	82.3	78.1	83.8	279.2	323.1	76.3	2.4
YoY Change (%)	35.2	9.1	6.6	17.4	13.9	16.5	14.1	8.2	18.4	15.9	15.7	5.7	
EBITDA	20.5	20.0	20.3	17.7	21.3	22.0	21.7	21.7	23.8	78.4	88.8	20.4	6.3
YoY Change (%)	97.8	10.7	-1.3	34.0	4.0	10.3	7.1	7.1	34.7	26.2	13.3	0.7	
Margins (%)	30.3	29.0	28.1	24.9	27.7	27.5	26.4	27.8	28.4	28.1	27.5	26.8	
Amortization	3.6	3.8	3.9	3.5	3.8	4.0	4.7	4.7	4.9	14.8	17.4	4.7	
EBIT	16.9	16.1	16.4	14.1	17.5	18.1	17.0	17.0	18.9	63.5	71.4	15.7	
Other Income	1.1	1.6	2.0	1.7	1.4	2.6	0.5	0.5	0.7	6.4	5.1	1.1	
PBT before EO expenses	18.0	17.7	18.4	15.8	18.8	20.7	17.5	17.5	19.6	69.9	76.5	16.8	3.8
One-off inc./(exp.)	0.5	1.4	-0.1	0.2	0.0	-1.5	1.3	1.3	0.0	2.0	-0.2	0.0	
Profit before Tax	18.5	19.1	18.3	16.0	18.8	19.2	18.7	18.7	19.6	71.9	76.3	16.8	11.4
Tax	4.4	4.3	4.5	2.9	4.9	5.8	4.7	4.7	4.5	16.2	19.8	4.0	
Rate (%)	24.0	22.7	24.5	18.4	26.0	30.0	25.1	25.1	22.9	22.5	26.0	23.9	
PAT	14.0	14.8	13.8	13.1	13.9	13.4	14.0	14.0	15.1	55.7	56.5	12.8	9.6
Adjusted PAT	13.7	13.3	13.8	12.1	13.9	13.6	13.2	13.2	13.2	52.8	53.9	11.9	10.7
YoY Change (%)	66.6	16.5	5.1	50.1	2.0	2.4	-4.3	-4.3	8.8	29.6	2.0	-13.6	
Margins (%)	20.3	19.3	19.1	17.1	18.1	17.0	16.0	16.9	15.7	18.9	16.7	15.6	
EPS	16.4	15.9	16.5	14.5	16.7	16.3	15.8	15.8	15.8	63.4	64.7	14.3	10.7

E: MOFSL Estimates, Note: 3Q-Adjusted column is adjusted for revenue from NRT acquisition

Key performance Indicators (Consolidated)											(INR b)	
Y/E March	FY24				FY25E				FY24	FY25E	FY25E	
	INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	3Q-Adj.	4QE	3QE	
North America	32.0	31.7	33.5	32.6	38.5	37.3	33.8	33.8	34.5	129.9	144.1	33.6
YoY Change (%)	79.5	13.2	9.6	28.8	20.3	17.6	1.0	1.0	5.8	27.7	10.9	0.4
Europe	5.1	5.3	5.0	5.2	5.3	5.8	12.1	6.1	11.9	20.5	35.0	5.7
YoY Change (%)	22.5	25.9	15.5	5.0	3.8	9.2	143.4	21.8	127.8	16.5	70.6	15.0
India	11.5	11.9	11.8	11.3	13.3	14.0	13.5	13.5	12.9	46.4	53.6	13.3
YoY Change (%)	3.9	3.1	4.7	10.5	15.4	17.8	14.1	14.1	14.6	5.4	15.5	12.5
Russia & Others CIS	7.6	8.0	8.2	7.2	7.4	9.0	9.4	9.4	9.9	30.9	35.7	7.9
YoY Change (%)	49.8	-1.2	-9.9	-4.0	-2.6	12.5	14.6	14.6	37.0	3.8	15.4	-4.0
Others	4.0	4.2	4.6	4.9	3.7	5.6	5.0	5.0	5.4	17.7	19.7	6.3
YoY Change (%)	-0.1	2.2	15.9	34.3	-5.3	32.1	7.0	7.0	10.0	12.8	10.9	35.0
PSAI	6.7	7.0	7.8	8.2	7.7	8.4	8.2	8.2	8.8	29.8	33.1	8.4
YoY Change (%)	-5.4	9.3	1.0	5.5	14.1	19.5	4.8	4.8	6.8	2.5	10.9	7.0
Cost Break-up												
COGS (% of Sales)	41.3	41.3	41.5	41.4	39.6	40.4	42.0	39.6	39.2	41.4	40.3	41.4
SG&A (% of Sales)	21.0	21.7	22.7	23.9	24.6	23.0	23.6	24.1	23.6	22.3	23.7	23.5
R&D Exp. (% of Sales)	7.4	7.9	7.7	9.7	8.1	9.1	8.1	8.5	8.8	8.2	8.5	8.3
Gross Margins (%)	58.7	58.7	58.5	58.6	60.4	59.6	58.0	60.4	60.8	58.6	59.7	58.6
EBITDA Margins (%)	30.3	29.0	28.1	24.9	27.7	27.5	26.4	27.8	28.4	28.1	27.5	26.8
EBIT Margins (%)	25.0	23.4	22.7	19.9	22.8	22.5	20.7	21.8	22.5	22.8	22.1	20.6

E: MOFSL Estimates, Note: 3Q-Adjusted column is adjusted for revenue from NRT acquisition




Management call highlights

- DRRD is fully integrated to manufacture abatacept as well as semaglutide.
- It got CRL for Iron sucrose, implying additional queries to be resolved before approval.
- Price erosion in the base portfolio affected growth in the NA market in 3Q.
- DRRD expects SGA expenses to be 28% of sales in FY25. It indicated R&D spend to be 8.5-9% of sales in FY25.
- R&D expenses stood at INR6.7b (8.5% of sales).
- DRRD launched Toripalimab, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma in India.
- DRRD launched Elobixibat, a first-in-class drug to treat chronic constipation, under the brand name BixiBat, in India.


Key exhibits

Exhibit 1: In CC terms, NA sales down ~1.4% YoY in 3QFY25




Source: MOFSL, Company

Exhibit 2: DF sales grew 14.1% YoY in 3QFY25




Source: MOFSL, Company

Exhibit 3: Gross profit increased 13.2% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 4: EBITDA increased 7.1% YoY in 3QFY25



Source: Company, MOFSL

Exhibit 5: R&D expenses as a proportion of sales at 8.1% in 1QFY25



Work-in-progress to offset g-Revlimid impact

Working on a differentiated portfolio for the US market

- In 9MFY25, NA sales posted robust 11% YoY growth to USD1.3b, largely led by strong traction in revlimid and an increase in sales volumes, partially offset by price erosion and market share loss in the base portfolio.
- While DRRD launched 11 new products during 9MFY25, the launch momentum is expected to be robust for FY25.
- There are 75 ANDAs and 4 NDAs under the 505(b)(2) route awaiting approval. Of these ANDAs, 44 are Para IVs and 20 have the potential to secure the 'First to File' status.
- Additionally, the company has filed Denosumab in the US through its partner Alvotech and plans to file Abacept in Dec'25. This product will provide a meaningful contribution from FY27-28 onward.
- Further, the company has received form 483 with seven observations for its Bollaram facility during the quarter.
- Over FY25-27, we expect US sales to decline 6% to ~INR127b (USD1.5b) due to the anticipated increase in competition in g-Revlimid from 4QFY26 onward.

New launches/in-licensing/JV to drive growth in the DF market

- In 9MFY25, India sales witnessed a healthy growth of 15.8% YoY to INR40.7b. The growth was driven by the in-licensed vaccine portfolio, new product launches and price hikes, and double-digit growth in derma, respiratory and vaccines.
- The company launched 22 products during 9M and is exploring some in-licensing and partnership opportunities.
- Further, the company operationalized its JV business in Aug'24 to undertake the nutraceutical and supplement products in India and Nepal, which would drive growth over the long term.
- We expect a sales CAGR of 14% to reach INR69.6b over FY25-27.

Geographical expansion to drive growth in the EM market

- In 9MFY25, EM sales grew 12% YoY to INR40.8b, led by market share expansion and new product launches, partly offset by unfavorable forex.
- Specifically, the Russian business witnessed 12% YoY growth due to price increases and improved volumes, partially offset by unfavorable currency exchange rates.
- We expect a sales CAGR of 12% to reach INR69b over FY25-27.

PSAI segment: Volume/new launches to aid growth

- In 9MFY25, the PSAI segment's revenue posted strong growth of 12.5% YoY to INR24.3b after a modest 2.5% YoY growth in sales in FY24. The growth was mainly driven by market share expansion, growth in services business, and revenues from new products.
- Further, the PSAI segment witnessed a gross margin expansion of 80bp YoY to 23%, led by an improvement in the product mix.
- We expect the PSAI business to post a 10% sales CAGR to reach INR40b over FY25-27.

Reiterate Neutral

- We lower our earnings estimates by 5%/3% for FY26/FY27, factoring in 1) a gradual pick-up in potential launches in the NA market, thereby limiting visibility for growth beyond g-Revlimid; and b) price erosion in the base portfolio. We value DRRD at 20x 12M forward earnings to arrive at a TP of INR1,330.
- DRRD is implementing efforts to build growth levers like a) semaglutide opportunities in Canada and other emerging markets, and b) a niche pipeline (abatacept biosimilar/Iron-sucrose) for the NA market. However, the timing of commercial success of these opportunities and higher anticipated competition in g-Revlimid may keep growth in check for the next two years. Maintain Neutral.

Exhibit 6: P/E chart





Exhibit 7: EV/EBITDA chart



Story in charts

Exhibit 8: Expect sales CAGR of ~5.9% over FY25-27




Exhibit 9: NA sales to decline 6% over FY25-27




Exhibit 10: DF sales to exhibit 14% CAGR over FY25-27




Exhibit 11: PSAI to post 10% sales CAGR over FY25-27




Exhibit 12: EBITDA margin to contract 250bp over FY25-27




Exhibit 13: EBITDA to be on downtrend over FY25-27




Exhibit 14: R&D expense to settle at ~8% of sales by FY27





Exhibit 15: EPS to clock modest 2.7% CAGR over FY25-27



Source: Company, MOFSL

Source: Company, MOFSL

Financials and valuations

Income Statement									
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	(INR b) FY27E
Net Sales	152	167	190	212	241	279	323	350	362
Change (%)	7.1	10.1	13.3	11.9	13.5	15.9	15.7	8.4	3.4
Total Expenditure	123	132	145	167	179	201	234	254	271
EBITDA	29	35	45	45	62	78	89	96	90
Change (%)	27.2	21.4	26.4	0.5	38.3	26.2	13.3	8.4	-6.0
Margin (%)	19.1	21.1	23.6	21.2	25.8	28.1	27.5	27.5	25.0
Depreciation & Amort.	12	12	13	12	13	15	17	18	19
EBIT	17	23	32	33	49	64	71	78	72
Net Interest Exp	1	1	-2	-2	-3	-3	-3	-2	-2
One-off (Gains)/Losses	-2	8	8	6	-5	-2	1	0	0
PBT before EO Expense	18	14	26	29	58	69	73	80	73
Change (%)	56.5	14.7	35.9	10.5	39.5	29.6	9.5	6.3	-8.3
PBT after EO Expense	18	14	26	29	58	69	73	80	73
Tax	4	-1	9	9	15	16	20	19	18
Tax Rate (%)	20.5	-10.3	35.5	30.3	26.5	23.5	27.1	24.1	24.2
Reported PAT	19	19	18	24	44	56	53	62	57
Adjusted Net Profit	17	22	24	29	41	53	54	62	57
Change (%)	62.6	24.9	9.3	22.8	39.3	29.6	2.0	15.0	-8.3
Margin (%)	11.5	13.0	12.6	13.8	16.9	18.9	16.7	17.7	15.7

Balance Sheet									
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	(INR b) FY27E
Equity Share Capital	1	1	1	1	1	1	1	1	1
Reserves	139	155	176	190	230	280	329	387	440
Net Worth	140	156	176	191	231	281	330	388	441
Loans	34	18	29	34	13	20	19	18	17
Deferred Liabilities/Tax	-4	-12	-10	-13	-6	-10	-10	-10	-10
Capital Employed	171	162	195	212	238	291	340	397	449
Gross Block	115	126	144	161	178	203	200	209	217
Less: Accum. Deprn.	62	74	87	99	111	126	144	144	144
Net Fixed Assets	54	52	57	62	66	77	56	65	74
Investments	31	33	33	38	62	81	81	81	81
Goodwill/Intangibles	47	32	41	32	35	41	41	41	41
Curr. Assets	88	103	125	152	151	177	238	300	341
Inventory	34	35	45	51	49	64	59	71	60
Account Receivables	40	52	50	67	72	80	99	107	96
Cash and Bank Balance	2	2	15	15	6	7	51	90	152
Others	13	14	15	19	24	26	29	32	33
Curr. Liability & Prov.	50	58	60	72	77	86	76	91	88
Account Payables	14	15	18	26	26	31	26	34	27
Other Current Liabilities	36	43	42	47	50	55	50	56	61
Net Current Assets	39	45	65	79	74	91	162	210	252
Appl. of Funds	171	162	195	212	238	291	340	397	449

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	21.0	26.3	28.7	35.2	48.9	63.4	64.7	74.4	68.2
Cash EPS	35.5	41.3	44.1	49.4	64.2	81.2	85.6	96.2	90.8
BV/Share	169.0	187.9	212.6	229.0	277.3	336.8	396.3	465.7	528.9
DPS	4.0	4.7	5.0	4.1	4.1	4.3	4.3	4.3	4.3
Payout (%)	21.3	23.5	26.8	16.9	9.0	7.5	8.0	6.7	7.4
Valuation (x)									
P/E	61.3	49.1	44.9	36.7	26.4	20.3	19.9	17.3	18.9
P/BV	7.6	6.9	6.1	5.6	4.7	3.8	3.3	2.8	2.4
EV/Sales	7.1	6.3	5.6	5.0	4.2	3.6	3.0	2.6	2.4
EV/EBITDA	36.9	29.9	23.6	23.5	16.4	12.8	10.8	9.6	9.5
Dividend Yield (%)	0.3	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Return Ratios (%)									
ROIC	10.8	21.9	17.0	18.0	23.1	27.6	26.7	28.5	25.8
RoE	13.1	14.7	14.3	16.0	19.3	20.7	17.6	17.3	13.7
RoCE	8.9	17.4	11.8	12.3	15.9	18.4	16.4	15.9	12.8
Working Capital Ratios									
Fixed Asset Turnover (x)	1.4	1.4	1.4	1.4	1.4	1.5	1.6	1.7	1.7
Debtor (Days)	97	100	98	100	106	100	101	107	102
Inventory (Days)	75	75	77	83	75	73	69	68	66
Payable (Days)	32	32	32	38	39	38	32	32	31
Leverage Ratio									
Current Ratio (x)	1.8	1.8	2.1	2.1	2.0	2.1	3.1	3.3	3.9
Net Debt/Equity (x)	0.0	-0.1	-0.2	-0.2	-0.3	-0.3	-0.5	-0.6	-0.8

Cash Flow Statement

(INR b)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Op. Profit/(Loss) before Tax	22	26	35	39	54	70	77	81	75
Depreciation	12	12	13	12	13	15	17	18	19
Interest/Dividends Recd.	-6	5	6	3	-7	-5	0	-1	-1
Direct Taxes Paid	-4	1	-9	-9	-15	-16	-20	-19	-18
(Inc)/Dec in WC	1	-6	-7	-15	-4	-16	-26	-9	19
CF from Operations	25	38	38	30	40	48	48	70	93
EO Expense	0	0	-6	-5	0	0	0	0	0
CF from Operations	29	39	44	34	40	48	48	70	93
(inc)/dec in FA	-9	5	-27	-8	-20	-31	3	-9	-9
Free Cash Flow	16	43	11	22	20	17	51	61	85
(Pur)/Sale of Investments	3	-2	0	-5	-24	-19	0	0	0
Others	-2	-7	0	-13	0	0	0	0	0
CF from Investments	-8	-5	-27	-26	-44	-50	3	-9	-9
Change in net worth	0	1	2	-5	0	-2	1	0	0
(Inc)/Dec in Debt	-17	-16	12	4	-20	7	-1	-1	-1
Other Items	-1	-5	-13	9	1	2	2	-9	2
Dividend Paid	-4	-5	-5	-4	-4	-4	-4	-4	-4
CF from Fin. Activity	-21	-25	-5	4	-23	2	-2	-14	-3
Inc/Dec of Cash	0	8	13	12	-27	0	49	48	81
Add: Beginning Balance	3	2	2	15	15	6	7	51	90
Closing Balance	2	11	15	27	-12	6	56	99	171
FX Impact	0	0	0	0	0	0	0	0	0
FX impact net of bank balances	0	-9	0	-12	18	1	-5	-9	-20
Closing Balance	2	2	15	15	6	7	51	90	152

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Lis%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.

MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.

5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.